380 related articles for article (PubMed ID: 11208838)
1. Lack of prognostic significance of p53 and K-ras mutations in primary resected non-small-cell lung cancer on E4592: a Laboratory Ancillary Study on an Eastern Cooperative Oncology Group Prospective Randomized Trial of Postoperative Adjuvant Therapy.
Schiller JH; Adak S; Feins RH; Keller SM; Fry WA; Livingston RB; Hammond ME; Wolf B; Sabatini L; Jett J; Kohman L; Johnson DH
J Clin Oncol; 2001 Jan; 19(2):448-57. PubMed ID: 11208838
[TBL] [Abstract][Full Text] [Related]
2. A novel molecular staging protocol for non-small cell lung cancer.
Miyake M; Adachi M; Huang C; Higashiyama M; Kodama K; Taki T
Oncogene; 1999 Apr; 18(14):2397-404. PubMed ID: 10327061
[TBL] [Abstract][Full Text] [Related]
3. Mutations of p53 and K-ras genes as prognostic factors for non-small cell lung cancer.
Huang CL; Taki T; Adachi M; Konishi T; Higashiyama M; Kinoshita M; Hadama T; Miyake M
Int J Oncol; 1998 Mar; 12(3):553-63. PubMed ID: 9472092
[TBL] [Abstract][Full Text] [Related]
4. Prognostic and predictive importance of p53 and RAS for adjuvant chemotherapy in non small-cell lung cancer.
Tsao MS; Aviel-Ronen S; Ding K; Lau D; Liu N; Sakurada A; Whitehead M; Zhu CQ; Livingston R; Johnson DH; Rigas J; Seymour L; Winton T; Shepherd FA
J Clin Oncol; 2007 Nov; 25(33):5240-7. PubMed ID: 18024870
[TBL] [Abstract][Full Text] [Related]
5. Prognostic significance of K-ras codon 12 mutations in patients with resected stage I and II non-small-cell lung cancer.
Graziano SL; Gamble GP; Newman NB; Abbott LZ; Rooney M; Mookherjee S; Lamb ML; Kohman LJ; Poiesz BJ
J Clin Oncol; 1999 Feb; 17(2):668-75. PubMed ID: 10080613
[TBL] [Abstract][Full Text] [Related]
6. P53 and K-ras mutations are frequent events in microscopically negative surgical margins from patients with nonsmall cell lung carcinoma.
Jassem J; Jassem E; Jakóbkiewicz-Banecka J; Rzyman W; Badzio A; Dziadziuszko R; Kobierska-Gulida G; Szymanowska A; Skrzypski M; Zylicz M
Cancer; 2004 May; 100(9):1951-60. PubMed ID: 15112277
[TBL] [Abstract][Full Text] [Related]
7. p53 immunostaining positivity is associated with reduced survival and is imperfectly correlated with gene mutations in resected non-small cell lung cancer. A preliminary report of LCSG 871.
Carbone DP; Mitsudomi T; Chiba I; Piantadosi S; Rusch V; Nowak JA; McIntire D; Slamon D; Gazdar A; Minna J
Chest; 1994 Dec; 106(6 Suppl):377S-381S. PubMed ID: 7988268
[TBL] [Abstract][Full Text] [Related]
8. Implications and prognostic value of K-ras mutation for early-stage lung cancer in women.
Nelson HH; Christiani DC; Mark EJ; Wiencke JK; Wain JC; Kelsey KT
J Natl Cancer Inst; 1999 Dec; 91(23):2032-8. PubMed ID: 10580029
[TBL] [Abstract][Full Text] [Related]
9. Multiple molecular marker testing (p53, C-Ki-ras, c-erbB-2) improves estimation of prognosis in potentially curative resected non-small cell lung cancer.
Schneider PM; Praeuer HW; Stoeltzing O; Boehm J; Manning J; Metzger R; Fink U; Wegerer S; Hoelscher AH; Roth JA
Br J Cancer; 2000 Aug; 83(4):473-9. PubMed ID: 10945494
[TBL] [Abstract][Full Text] [Related]
10. A universal method for the mutational analysis of K-ras and p53 gene in non-small-cell lung cancer using formalin-fixed paraffin-embedded tissue.
Sarkar FH; Valdivieso M; Borders J; Yao KL; Raval MM; Madan SK; Sreepathi P; Shimoyama R; Steiger Z; Visscher DW
Diagn Mol Pathol; 1995 Dec; 4(4):266-73. PubMed ID: 8634783
[TBL] [Abstract][Full Text] [Related]
11. Ki-ras mutation and p53 overexpression predict the clinical behavior of colorectal cancer: a Southwest Oncology Group study.
Ahnen DJ; Feigl P; Quan G; Fenoglio-Preiser C; Lovato LC; Bunn PA; Stemmerman G; Wells JD; Macdonald JS; Meyskens FL
Cancer Res; 1998 Mar; 58(6):1149-58. PubMed ID: 9515799
[TBL] [Abstract][Full Text] [Related]
12. Mutations in exon 7 and 8 of p53 as poor prognostic factors in patients with non-small cell lung cancer.
Huang C; Taki T; Adachi M; Konishi T; Higashiyama M; Miyake M
Oncogene; 1998 May; 16(19):2469-77. PubMed ID: 9627113
[TBL] [Abstract][Full Text] [Related]
13. Mutations of the p53 gene as a predictor of poor prognosis in patients with non-small-cell lung cancer.
Mitsudomi T; Oyama T; Kusano T; Osaki T; Nakanishi R; Shirakusa T
J Natl Cancer Inst; 1993 Dec; 85(24):2018-23. PubMed ID: 8246288
[TBL] [Abstract][Full Text] [Related]
14. Do molecular markers predict survival in non-small-cell lung cancer?
Greatens TM; Niehans GA; Rubins JB; Jessurun J; Kratzke RA; Maddaus MA; Niewoehner DE
Am J Respir Crit Care Med; 1998 Apr; 157(4 Pt 1):1093-7. PubMed ID: 9563724
[TBL] [Abstract][Full Text] [Related]
15. Immunohistochemical analysis of C/EBPalpha in non-small cell lung cancer reveals frequent down-regulation in stage II and IIIA tumors: a correlative study of E3590.
Costa DB; Li S; Kocher O; Feins RH; Keller SM; Schiller JH; Johnson DH; Tenen DG; Halmos B
Lung Cancer; 2007 Apr; 56(1):97-103. PubMed ID: 17239984
[TBL] [Abstract][Full Text] [Related]
16. Prognostic significance of p53 and ras p21 expression in nonsmall cell lung cancer.
Fujino M; Dosaka-Akita H; Harada M; Hiroumi H; Kinoshita I; Akie K; Kawakami Y
Cancer; 1995 Dec; 76(12):2457-63. PubMed ID: 8625071
[TBL] [Abstract][Full Text] [Related]
17. Plasma DNA, microsatellite alterations, and p53 tumor mutations are associated with disease-free survival in radically resected non-small cell lung cancer patients: a study of the perugia multidisciplinary team for thoracic oncology.
Ludovini V; Pistola L; Gregorc V; Floriani I; Rulli E; Piattoni S; Di Carlo L; Semeraro A; Darwish S; Tofanetti FR; Stocchi L; Mihaylova Z; Bellezza G; Del Sordo R; Daddi G; Crinò L; Tonato M
J Thorac Oncol; 2008 Apr; 3(4):365-73. PubMed ID: 18379354
[TBL] [Abstract][Full Text] [Related]
18. Molecular staging of non-small cell lung cancer according to K-ras genotypes.
Rosell R; Monzó M; Pifarré A; Ariza A; Sánchez JJ; Moreno I; Maurel J; López MP; Abad A; de Anta JM
Clin Cancer Res; 1996 Jun; 2(6):1083-6. PubMed ID: 9816271
[TBL] [Abstract][Full Text] [Related]
19. Prognostic significance of K-ras, p53, bcl-2, PCNA, CD34 in radically resected non-small cell lung cancers.
Grossi F; Loprevite M; Chiaramondia M; Ceppa P; Pera C; Ratto GB; Serrano J; Ferrara GB; Costa R; Boni L; Ardizzoni A
Eur J Cancer; 2003 Jun; 39(9):1242-50. PubMed ID: 12763212
[TBL] [Abstract][Full Text] [Related]
20. K-ras and p53 mutations are an independent unfavourable prognostic indicator in patients with non-small-cell lung cancer.
Fukuyama Y; Mitsudomi T; Sugio K; Ishida T; Akazawa K; Sugimachi K
Br J Cancer; 1997; 75(8):1125-30. PubMed ID: 9099959
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]